Alinidine

From Self-sufficiency
Revision as of 00:03, 9 June 2010 by حسن علي البط (Talk) (Adding category Category:Alkenes (using HotCat))

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Alinidine
File:Alinidine.png
Systematic (IUPAC) name
N-(2,6-dichlorophenyl)-N-(prop-2-en-1-yl)-4,5-dihydro-1H-imidazol-2-amine
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number 33178-86-8
ATC code none
PubChem CID 36354
ChemSpider 33429
Chemical data
Formula C12H13Cl2N3
Molar mass 270.16 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Alinidine (ST567) is a negative chronotrope that was developed in the 70's and 80's. It causes bradycardia by inhibiting the pacemaker current by altering the maximal channel conductance and alter the voltage threshold.[1] The development of alinidine was halted because it was not sufficiently specific for its target. It also has a blocking effect on calcium channels and potassium channels. It also causes elongation of re-polarisation after an action potential.[2]

Alinidine did not improve outcomes among patients with acute myocardial infarction in a randomized controlled trial.[3]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


  1. Snyders DJ, Van Bogaert P-P: Alinidine modifies the pacemaker current in sheep Purkinje fibers. Pflugers Arch 1987, 410:83-91
  2. Current Opinion in Pharmacology 2007, 7:208–213
  3. Van de Werf F, Janssens L, Brzostek T, Mortelmans L, Wackers FJ, Willems GM; et al. (1993). "Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy". J Am Coll Cardiol. 22 (2): 407–16. PMID 8335810.